Joseph C. Beyer

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

Kirsten Achilles Poon, Kelly M. Flagella, Joseph C. Beyer et al. · Toxicology and Applied Pharmacology · 2013 · 194 citations · Full text

Pharmacy, Oncology, Pharmacology +17

PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS

Jacques Gaudreault, David Fei, Joseph C. Beyer et al. · Retina · 2007 · 187 citations

Medicine, Ophthalmology, Pharmacology +17

Immunogenicity/Hypersensitivity of Biologics

Michael W. Leach, James B. Rottman, M. Benjamin Hock et al. · Toxicologic Pathology · 2013 · 107 citations

Life Sciences, Hematology, Immunology +17

Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase

Tanja S. Zabka, Jatinder Singh, Preeti Dhawan et al. · Toxicological Sciences · 2014 · 85 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

Amita Patnaik, Patricia LoRusso, Wells A. Messersmith et al. · Cancer Chemotherapy and Pharmacology · 2014 · 80 citations

Medicine, Oncology, Cancer Pharmacology +12